Humoral Leukocyte Adherence Inhibition Research Articles

Modified humoral leukocyte adherence inhibition test for detection of lung cancer : Kubasova T, Horvath M, Szarvas I, Beke CS, Koteles GJ. ‘Frederic Joliot-Curie’, National Research Institute for Radiobiology and Radiohygiene, H-1775 Budapest. Oncology 1989;46:386-90

Modified humoral leukocyte adherence inhibition test for detection of lung cancer : Kubasova T, Horvath M, Szarvas I, Beke CS, Koteles GJ. ‘Frederic Joliot-Curie’, National Research Institute for Radiobiology and Radiohygiene, H-1775 Budapest. Oncology 1989;46:386-90

Modified Humoral Leukocyte Adherence Inhibition Test for Detection of Lung Cancer

The freshly separated indicator cells (suspension of leukocytes) used in humoral leukocyte adherence inhibition test were labeled either with 14C-amino acid mixture or 3H-concanavalin A (3H-ConA). Instead of counting the adherent cells, the amount of 'adherent' radioactivity was measured by a liquid scintillation spectrometer. By the modified method, sera from 25 lung-carcinoma-bearing patients as well as serum samples from 21 healthy persons were examined in the presence of crude antigens prepared from 'normal' lung tissue or lung tumors of various histologic types. Although the results demonstrated high specificity and reproducibility of both methods, the binding of 3H-ConA to the surface of adherent cells is more expressed and assures higher levels of radioactivity.

Humoral leukocyte adherence inhibition response in patients with oral cancer.

Antitumor immunity was assessed in a group of 10 patients suffering from squamous cell carcinoma of the oral cavity using the humoral leukocyte adherence inhibition assay (H-LAI). A tumor extract from a person with cancer of the tongue was used as antigen. Sera from five patients with carcinoma of the tongue were all positive in the test. Of the other five patients, three had cancer of the lips while in two patients the type was unspecified. All patients except one with cancer of the lips gave a positive response in the test. Thus, of the 10 patients with carcinoma of the oral cavity, nine responded. Among nine controls, one person gave a positive response.

Cell-populations involved in the humoral leukocyte adherence inhibition reaction. The T8-suppressor/cytotoxic cells are both effectors and responders

In an attempt to identify the cell subpopulation involved in the humoral leukocyte adherence inhibition (H-LAI) reaction, mononuclear leukocytes were fractionated and the response with the different cell populations was measured in the H-LAI assay using sera from lung cancer patients and a lung cancer associated antigen. The monocytes were found to exhibit a suppressive effect on the H-LAI response. The B-lymphocytes seemed not to take an active part in the reaction. Depletion of the T-lymphocytes abolished the reaction. Subsequent studies on the T-lymphocyte subpopulations revealed that removal of the T 4-cells had little effect while removal of the T 8-cells resulted in complete abrogation of the H-LAI response. Direct blocking by monoclonal antibodies against the T 4 and T 8 surface determinants gave additional support for the T 8-cell dependency of the H-LAI assay. The cells that specifically were induced to loose adherence in the H-LAI assay upon incubation with serum from a lung cancer patient and lung cancer associated antigen were also analyzed. Compared to the total mononuclear leukocyte population, the relative content of monocytes and B-cells were lower in the non-adherent population. An increase was found in the relative number of T-cells. While the relative number of T 4-cells decreased, the content of T 8-cells was significantly increased. Furthermore, a direct correlation was found between the loss of adherence of the T 8-subpopulation and the index of the H-LAI response. The present study indicates the T 8-subpopulation of the T-lymphocytes to be involved both in the effector and responder side of the H-LAI reaction and gives implications for an immunological reaction behind the response of the H-LAI assay.

Humoral leukocyte adherence inhibition (H-LAI) in the surgical and radiation treatment of lung cancer

Humoral leukocyte adherence inhibition (H-LAI) in the surgical and radiation treatment of lung cancer

Humoral leukocyte adherence inhibition (H-LAI) for the diagnosis of head and neck cancer with myelin basic protein antigen

Humoral leukocyte adherence inhibition (H-LAI) for the diagnosis of head and neck cancer with myelin basic protein antigen

Use of radio-labelled indicator cells in the humoral leukocyte adherence inhibition (H-LAI) test

Use of radio-labelled indicator cells in the humoral leukocyte adherence inhibition (H-LAI) test

Detection of cancer with the humoral leukocyte adherence inhibition assay

Detection of cancer with the humoral leukocyte adherence inhibition assay

Detection of ovarian cancer by the humoral leukocyte adherence inhibition test using a purified tumor-associated antigen

The defined, purified ovarian cancer-associated antigen, NB/70K, was used as tumor antigen in the humoral leukocyte adherence inhibition (H-LAI) assay. Bell-shaped dose-response relationships were obtained with increasing concentration of NB/70K and constant serum concentration from ovarian cancer patients. The concentrations of NB/70K used in this study were 100–250 times less than what had been used in previous H-LAI studies with crude antigen extracts. The response rate of ovarian cancer patients was greatly influenced by the stage of the disease. Thus 75% ( 6 8 ) of the patients with disease restricted to the pelvis (stages I and II) reacted while only 20% ( 5 24 ) of the patients with more advanced stages (stages III and IV) gave response. Of patients with other gynecological cancers, 17% ( 1 6 ) were positive and only 8% ( 1 13 ) of patients with other malignant diseases reacted. One of the 11 controls (9%) was found to give positive response. The importance of the present investigation was the finding that a defined, purified, cancer-associated antigen elicited reactivity in the H-LAI assay and that a high sensitivity for detection of early stages of ovarian cancer was obtained with this antigen. The results suggest that TAAs involved in immune recognition of cancer can be identified by the H-LAI assay.

The humoral leukocyte adherence inhibition test in the investigation of lung cancer treated by surgery and radiotherapy.

17 operable and 13 inoperable lung cancer patients entered the study. In all patients, the humoral leukocyte adherence inhibition (H-LAI) test was positive before treatment. 7-20 days after surgery the H-LAI values decreased to normal levels in 8/8 cases. On radiotherapy, the same decrease was valid in 7/9 patients. Two exceptions in which no H-LAI reduction could be observed were in correlation with tumor progression.

Purification of a cancer-associated protein factor in serum of lung cancer patients

The serum factor responsible for the humoral leukocyte adherence inhibition (H-LAI) reaction in lung cancer patients has been purified. It is precipitable by ammonium sulfate between 30–70% saturation. On DEAE ion exchange chromatography activity is eluted in the 0.12-0.2 M acetate fraction. The serum factor has affinity for Con A. This gives evidence for a glycoprotein nature of the factor. Electrophoresis indicates an apparent mol. wt of 71,000 dalton. The data suggest that the protein can be separated into subunits of 43,000 and 28,000 dalton under reducing conditions. Isoelectric focusing gives a mean pl of 4.5. The applied fractionation procedure gave a 1120-fold purification relative to lung cancer serum. Antiserum against the purified factor has been produced in rabbits. The factor can be demonstrated in high concentrations in serum of lung cancer patients, but is also found in smaller quantities in sera of other types of cancer. Minor quantities are present in normal serum. The results suggest that quantitation of the H-LAI factor can be used in cancer diagnosis.

The humoral leukocyte adherence inhibition in the discrimination among histologic types of lung cancer.

In an attempt to differentiate among histologic types of lung cancer, a modified humoral leukocyte adherence inhibition (H-LAI) assay was used. All types of lung cancer gave positive H-LAI indices against both homologous and autologous tumor extracts of the relevant histologic types. Positive H-LAI values were obtained even with unrelated tumor extracts. Cross-reactivity suggests that common antigen determinants or antigens of broad specificity play a role in the H-LAI assay.

A serum immune factor in detection of an occupational group with increased risk for lung and nose cancer

Epidemiological studies have demonstrated that workers in the nickel refinery industry have an increased risk for respiratory tract carcinoma. In the present study, serum from 51 workers at a Norwegian nickel refinery have been tested against lung, nasal and breast carcinoma antigens in the humoral leukocyte adherence inhibition test. The breast cancer antigen was used as a non-specific antigen. The frequency of positive response against the lung carcinoma antigen was significantly higher among the refinery workers ( 21 51 ) than in the controls ( 3 17 ) ( P = 0.07). Moreover, among workers employed for 10 years or more, the response was higher than found for workers with shorter employment. Of the nickel workers with nasal dysplasia, 56% ( 15 27 ) gave a positive reaction against the lung carcinoma antigen compared to 25% ( 6 24 ) of the workers without dysplasia ( P = 0.03). The same trends were also found for the nasal carcinoma antigen. The study gives further support for the usefulness of the humoral leukocyte adherence inhibition test in identification of individuals with an increased risk for developing cancer.

Role of immune complexes in the humoral leukocyte adherence inhibition test

The humoral leukocyte adherence inhibition (H-LAI) assay has recently been found to measure an antitumor immunefactor. In this assay, trypsinized leukocytes from control persons are used as indicator cells and 0,25% serum from the patient is added to the assay system together with the relevant tumor antigen.

Role of circulating antibodies in the humoral leukocyte adherence inhibition response of lung and breast cancer patients

A modified leukocyte adherence inhibition (H-LAI) assay has recently been developed in which 0.25% serum from the patient is added to the assay system in combination with the relevant antigen. Trypsinized leukocytes from control persons are used as indicator cells. In the present work, the nature of the humoral factor in serum from breast and lung cancer patients is studied. 3.5 M KCl extracts from the cell lines MCF-7 and Calu-1 were used as breast and lung cancer antigen, respectively. It was found that the humoral factor involved in the H-LAI response was precipitated from the sera by addition of ammonium sulphate to 50% saturation. This factor could be removed by passage through an affinity column with the relevant antigen bound to the matrix. Stable complexes were formed between the humoral factor and the relevant antigen, and could be precipitated by polyethylene glycol. When different anti-immunoglobulins were added to the sera, the humoral factor was specifically removed by addition of anti-IgG antibodies. The data presented indicate that the humoral factor in sera from patients with breast and lung cancer is anti-tumor antibodies of IgG nature.